Vergaro Viviana, Civallero Monica, Citti Cinzia, Cosenza Maria, Baldassarre Francesca, Cannazza Giuseppe, Pozzi Samantha, Sacchi Stefano, Fanizzi Francesco Paolo, Ciccarella Giuseppe
Dipartimento di Scienze e Tecnologie Biologiche e Ambientali, Università del Salento & UdR INSTM di Lecce, Campus Universitario, Via Monteroni, 73100 Lecce, Italy.
Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena & Reggio Emilia, via Campi 287, 41125 Modena, Italy.
Cancers (Basel). 2018 Jan 25;10(2):31. doi: 10.3390/cancers10020031.
Owing to their nano-sized porous structure, CaCO₃ nanocrystals (CaCO₃NCs) hold the promise to be utilized as desired materials for encapsulating molecules which demonstrate wide promise in drug delivery. We evaluate the possibility to encapsulate and release NVP-BEZ235, a novel and potent dual PI3K/mTOR inhibitor that is currently in phase I/II clinical trials for advanced solid tumors, from the CaCO₃NCs. Its chemical nature shows some intrinsic limitations which induce to administer high doses leading to toxicity; to overcome these problems, here we proposed a strategy to enhance its intracellular penetration and its biological activity. Pristine CaCO₃ NCs biocompatibility, cell interactions and internalization in in vitro experiments on T-cell lymphoma line, were studied. Confocal microscopy was used to monitor NCs-cell interactions and cellular uptake. We have further investigated the interaction nature and release mechanism of drug loaded/released within/from the NCs using an alternative approach based on liquid chromatography coupled to mass spectrometry. Our approach provides a good loading efficiency, therefore this drug delivery system was validated for biological activity in T-cell lymphoma: the anti-proliferative test and western blot results are very interesting because the proposed nano-formulation has an efficiency higher than free drug at the same nominal concentration.
由于其纳米级多孔结构,碳酸钙纳米晶体(CaCO₃NCs)有望成为用于封装分子的理想材料,这些分子在药物递送方面具有广阔前景。我们评估了从CaCO₃NCs中封装和释放NVP-BEZ235的可能性,NVP-BEZ235是一种新型且有效的双PI3K/mTOR抑制剂,目前正处于针对晚期实体瘤的I/II期临床试验阶段。其化学性质存在一些内在局限性,导致需要高剂量给药从而引发毒性;为克服这些问题,我们在此提出一种策略,以增强其细胞内穿透能力及其生物活性。研究了原始CaCO₃ NCs在T细胞淋巴瘤细胞系体外实验中的生物相容性、细胞相互作用和内化情况。共聚焦显微镜用于监测NCs与细胞的相互作用以及细胞摄取。我们还使用基于液相色谱-质谱联用的另一种方法,进一步研究了药物在NCs内/从NCs中加载/释放的相互作用性质和释放机制。我们的方法具有良好的负载效率,因此该药物递送系统在T细胞淋巴瘤中的生物活性得到了验证:抗增殖试验和蛋白质印迹结果非常有趣,因为在相同标称浓度下,所提出的纳米制剂的效率高于游离药物。